Literature DB >> 23238012

Cell-type, dose, and mutation-type specificity dictate mutant p53 functions in vivo.

Ming Kei Lee1, Wei Wei Teoh, Beng Hooi Phang, Wei Min Tong, Zhao Qi Wang, Kanaga Sabapathy.   

Abstract

The specific roles of mutant p53's dominant-negative (DN) or gain-of-function (GOF) properties in regulating acute response and long-term tumorigenesis is unclear. Using "knockin" mouse strains expressing varying R246S mutant levels, we show that the DN effect on transactivation is universally observed after acute p53 activation, whereas the effect on cellular outcome is cell-type specific. Reducing mutant p53 levels abrogated the DN effect. Mutant p53's DN effect protected against radiation-induced death but did not accentuate tumorigenesis. Furthermore, the R246S mutant did not promote tumorigenesis compared to p53(-/-) mice in various models, even when MDM2 is absent, unlike the R172H mutant. Together, these data demonstrate that mutant p53's DN property only affects acute responses, whereas GOF is not universal, being mutation-type specific.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23238012     DOI: 10.1016/j.ccr.2012.10.022

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  43 in total

Review 1.  TP53 Mutations in Head and Neck Squamous Cell Carcinoma and Their Impact on Disease Progression and Treatment Response.

Authors:  Ge Zhou; Zhiyi Liu; Jeffrey N Myers
Journal:  J Cell Biochem       Date:  2016-06-03       Impact factor: 4.429

Review 2.  Ceramide Signaling and p53 Pathways.

Authors:  Kristen A Jeffries; Natalia I Krupenko
Journal:  Adv Cancer Res       Date:  2018-06-01       Impact factor: 6.242

Review 3.  Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others.

Authors:  Kanaga Sabapathy; David P Lane
Journal:  Nat Rev Clin Oncol       Date:  2017-09-26       Impact factor: 66.675

4.  Mutant p53 Gains Its Function via c-Myc Activation upon CDK4 Phosphorylation at Serine 249 and Consequent PIN1 Binding.

Authors:  Peng Liao; Shelya X Zeng; Xiang Zhou; Tianjian Chen; Fen Zhou; Bo Cao; Ji Hoon Jung; Giannino Del Sal; Shiwen Luo; Hua Lu
Journal:  Mol Cell       Date:  2017-12-07       Impact factor: 17.970

5.  Cancer-specific mutations in p53 induce the translation of Δ160p53 promoting tumorigenesis.

Authors:  Marco M Candeias; Masatoshi Hagiwara; Michiyuki Matsuda
Journal:  EMBO Rep       Date:  2016-10-04       Impact factor: 8.807

Review 6.  Mutant TP53 posttranslational modifications: challenges and opportunities.

Authors:  Thuy-Ai Nguyen; Daniel Menendez; Michael A Resnick; Carl W Anderson
Journal:  Hum Mutat       Date:  2014-02-11       Impact factor: 4.878

7.  A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies.

Authors:  Steffen Boettcher; Peter G Miller; Rohan Sharma; Marie McConkey; Matthew Leventhal; Andrei V Krivtsov; Andrew O Giacomelli; Waihay Wong; Jesi Kim; Sherry Chao; Kari J Kurppa; Xiaoping Yang; Kirsten Milenkowic; Federica Piccioni; David E Root; Frank G Rücker; Yael Flamand; Donna Neuberg; R Coleman Lindsley; Pasi A Jänne; William C Hahn; Tyler Jacks; Hartmut Döhner; Scott A Armstrong; Benjamin L Ebert
Journal:  Science       Date:  2019-08-09       Impact factor: 47.728

8.  Amino-terminal p53 mutations lead to expression of apoptosis proficient p47 and prognosticate better survival, but predispose to tumorigenesis.

Authors:  Beng Hooi Phang; Rashidah Othman; Gaelle Bougeard; Ren Hui Chia; Thierry Frebourg; Choong Leong Tang; Peh Yean Cheah; Kanaga Sabapathy
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-02       Impact factor: 11.205

9.  Inactivation of Mdm2 restores apoptosis proficiency of cooperativity mutant p53 in vivo.

Authors:  Boris Klimovich; Thorsten Stiewe; Oleg Timofeev
Journal:  Cell Cycle       Date:  2019-11-21       Impact factor: 4.534

10.  Mutant p53 promotes tumor progression and metastasis by the endoplasmic reticulum UDPase ENTPD5.

Authors:  Fotini Vogiatzi; Dominique T Brandt; Jean Schneikert; Jeannette Fuchs; Katharina Grikscheit; Michael Wanzel; Evangelos Pavlakis; Joël P Charles; Oleg Timofeev; Andrea Nist; Marco Mernberger; Eva J Kantelhardt; Udo Siebolts; Frank Bartel; Ralf Jacob; Ariane Rath; Roland Moll; Robert Grosse; Thorsten Stiewe
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.